KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Research & Development · Q4 FY2026 · quarter ended Dec 2025
Research & development of $12.42M in Q4 FY2026
Q4 FY2026 research & development was $12.42M. Trailing-twelve-month research & development was $48.42M.
Context
- Research & development amounted to 75.6% of revenue in FY2026.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $12.42M or moves back toward the trailing-twelve-month quarterly average of $12.11M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 55.64M USD
- Year-over-year change
- -22.4%
- 4-year CAGR
- -5.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | 55.64M | -22.4% |
| FY2025 | 2025-04-30 | 71.71M | -16.8% |
| FY2024 | 2024-04-30 | 86.17M | +7.3% |
| FY2023 | 2023-04-30 | 80.28M | +14.4% |
| FY2022 | 2022-04-30 | 70.17M | — |
Research & Development vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 research & development of $48.42M is the 9th highest of the 10 companies compared; the peer median is $123.67M.
- Research & development amounts to 41.8% of revenue for KALV, versus a peer median of 249.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $230.13M | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Mar 2026 | $186.6M | +29.5% | +0.6% | 336.0% | |
| LTM Mar 2026 | $176.31M | +40.8% | +24.2% | — | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $96.67M | -53.8% | -0.2% | 166.8% | |
| LTM Mar 2026 | $94.95M | -15.8% | -17.7% | 119.9% | |
| LTM Mar 2026 | $70.57M | -39.3% | -10.3% | 713.3% | |
| LTM Dec 2025 | $48.42M | — | — | 41.8% | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| Peer median (excluding KALV) | $123.67M | +29.5% | +0.6% | 249.3% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 73.62M |
| Cost of Revenue | 0 | 0 | 86.17M | 0 | 6.08M |
| Gross Profit | 0 | 0 | (86.17M) | 0 | 67.54M |
| Gross Margin | — | — | — | — | 91.7% |
| Research & Development | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
| Selling, General & Admin | 26.45M | 30.6M | 54.28M | 116.29M | 183.74M |
| Operating Expenses | 96.61M | 110.87M | 54.28M | 188M | 239.38M |
| Depreciation & Amortization | 564K | 718K | 816K | 941K | 1.45M |
| EBITDA | (80.75M) | (94.37M) | (134.28M) | (173.33M) | (150.62M) |
| EBITDA Margin | — | — | — | — | -204.6% |
| Operating Income | (96.61M) | (110.87M) | (140.45M) | (188M) | (171.84M) |
| Operating Margin | — | — | — | — | -233.4% |
| Interest Income | 1.09M | 2.23M | 3.9M | 6.44M | 8.68M |
| Interest Expense | 0 | 0 | 0 | 5.79M | 19.34M |
| Other Income / Expenses | 14.27M | 17.96M | 5.35M | 7.94M | 420K |
| Income Before Tax | (82.34M) | (92.91M) | (135.1M) | (180.05M) | (171.42M) |
| Pre-Tax Margin | — | — | — | — | -232.9% |
| Income Tax Expense | 0 | 0 | (8.45M) | 3.39M | (7.13M) |
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Net Margin | — | — | — | — | -223.2% |
| EPS (Basic) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| EPS (Diluted) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| Weighted Avg Shares | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
| Weighted Avg Shares (Diluted) | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.